成人VR视频 and PATH strengthen partnership to accelerate development of vaccines against diseases with epidemic or pandemic potential
Share
14 December 2023; Oslo, Norway; Seattle, Washington: The Coalition for Epidemic Preparedness Innovations () and today announced a renewed collaboration to accelerate the rapid development of vaccines against emerging infectious diseases, and in support of 成人VR视频's 100 Days Mission, a goal to reduce the time taken to develop safe and effective vaccines against pathogens with epidemic or pandemic potential to 100 days.
Under the terms of the 成人VR视频-PATH Implementing Partnership Agreement, PATH will help 成人VR视频 continue to enhance its capacities for project design and management, implementation, coordination and operational oversight. In doing so, PATH will also work with 成人VR视频 partners to provide such services that enable the rapid development of vaccines against pathogens with epidemic or pandemic potential, from proof of concept through to licensure.
To this end, PATH will work across multiple 成人VR视频-funded projects, including providing strategic, technical and scientific support for the clinical and manufacturing development process of vaccines, boosting innovative technology development, and facilitating capacity-strengthening initiatives that enhance local resources to help establish or improve research preparedness and emergency evidence generation for future outbreaks. In addition, to help ensure adequate vaccine uptake in the event of an outbreak, PATH will collaborate with 成人VR视频 to enhance support for communication and advocacy activities in low-resource communities affected by relevant pathogens.
This 成人VR视频-PATH partnership builds upon previous successful collaborations between the two organisations, including assisting 成人VR视频 with early-stage clinical trials for a vaccine candidate against the deadly Nipah virus, providing Phase 3 oversight and contracting of clinical trials for COVID-19 vaccine development, reviewing and evaluating alternative delivery devices for vaccines, and much more.
We are delighted to strengthen our existing partnership with PATH, who have supported 成人VR视频 in various capacities, almost since our inception, from clinical trial support to vaccine manufacturing, delivery and beyond. This renewed partnership builds upon and extends our potential areas for collaboration, helping to accelerate the development of safe, effective and equitably accessible vaccines against emerging infectious diseases in support of the 100 Days Mission. In doing so, the world will be better prepared to face future viral threats by developing pandemic-busting vaccines potentially within 100 days of being alerted to the threat.
We are excited to continue partnering with 成人VR视频 on accelerating equitable access to vaccines against future threats. We look forward to contributing to 成人VR视频's essential mission by leveraging our breadth of experience in vaccine development and implementation.
鈥抬狈顿厂鈥
Notes to Editors
About 成人VR视频
成人VR视频 is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.
成人VR视频 has supported the development of over 30 vaccine candidates against its priority pathogens鈥擟hikungunya virus, Ebola Virus Disease, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever virus and SARS-CoV-2鈥攁nd is a leading funder of research into broadly protective coronavirus vaccines, which could protect against future variants of COVID-19 as well as other coronaviruses with epidemic and pandemic potential. The organization has also invested in the development of rapid response platforms to develop vaccines against Disease X (the threat of an unknown virus).
成人VR视频 has overseen a number of scientific breakthroughs, including the first Phase 3 trial of a Chikungunya vaccine and the advancement of the first ever Nipah and Lassa vaccines into Phase 1 trials. The organization played a central role in the global response to COVID-19, supporting the development of one of the world's largest portfolios of vaccines against SARS-CoV-2, seven of which have been approved for domestic or global use. It also co-led COVAX, the global initiative to deliver fair and equitable access to COVID-19 vaccines, which has delivered approximately 2 billion doses of vaccine to 146 countries around the world.
成人VR视频's five-year plan for 2022-2026 aims to dramatically reduce or even eliminate the future risk of pandemics and epidemics. Central to the plan is 成人VR视频's goal to compress the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days. Achieving this 鈥100 Days Mission', which has been embraced by the G7 and G20, would give the world a fighting chance of containing a future outbreak before it can spread to become a global pandemic.
Visit our news page for the latest updates. Follow us via @成人VR视频vaccines, @DrRHatchett, LinkedIn, and Facebook.
About PATH
PATH is a global nonprofit dedicated to achieving health equity. With more than 40 years of experience forging multisector partnerships, and with expertise in science, economics, technology, advocacy, and dozens of other specialties, PATH develops and scales up innovative solutions to the world's most pressing health challenges.
Media contacts
成人VR视频
E: [email protected]
P: +44 7387 055214
PATH
Lindsay Bosslet, MPH
Email: [email protected]
New partnership aims to advance vaccine against MERS coronavirus
成人VR视频 partners with Rwandan-US Akagera Medicines to improve the delivery and accessibility of mRNA vaccines
